Eli Lilly and Company vs Sanofi S.A.: Strategic Comparison

This in-depth comparison examines Eli Lilly and Company and Sanofi S.A. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Sanofi S.A., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Sanofi S.A. is widest.

On the headline numbers, Eli Lilly and Company reports annual revenue of $45.0B against $44.6B for Sanofi S.A., while their respective market capitalizations stand at $700.0B and $107.8B. Eli Lilly and Company is headquartered in United States and Sanofi S.A. operates from France, and those different home markets shape how each company competes.

Eli Lilly and Company: Revenue at Eli Lilly went from $28.5 billion in 2022 to $45 billion in 2024. That $16.5 billion increase in two years is not a corporate turnaround story — it's the commercial harvest of a single molecule: tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. The drug became the fastest pharmaceutical product ever to reach $5 billion in annual sales, transforming a 148-year-old Midwestern company into one of America's most valuable corporations at a $700 billion market capitalization. The scientific lineage matters. Lilly produced the world's first commercially available insulin in 1923, giving type 1 diabetic patients who had previously faced certain death a reason to survive. That 1923 achievement planted the company in incretin biology — the study of gut hormones that regulate insulin secretion and appetite — where it would spend decades building intellectual and clinical depth. Tirzepatide is not a lucky discovery. It is the commercial output of that sustained investment. The SURMOUNT-5 trial made a specific claim that reshaped the competitive landscape: tirzepatide produced approximately 47% greater relative weight loss than semaglutide (Wegovy) in a direct head-to-head comparison. That's not a nuanced statistical edge — it's a clinically meaningful difference that gives physicians a reason to prescribe Zepbound over Novo Nordisk's product. The supply shortage that followed was the kind of problem that only hits companies whose demand has genuinely exceeded expectations. Retatrutide, Lilly's triple receptor agonist in Phase 3 development, showed average body weight reduction of approximately 24.2% over 48 weeks in a Phase 2 trial. If that number holds in Phase 3, it would represent the most effective pharmacological weight loss data ever published.

Sanofi S.A.: One drug — Dupixent — generated $14.3 billion in FY2024 sales and constituted 31.8 percent of Sanofi's total revenue. That single molecule, a biologic antibody that blocks the IL-4 and IL-13 signaling pathways implicated in atopic dermatitis and asthma, has been approved for seven conditions with an eighth — COPD — approved in 2024. More than one million patients receive it. The drug's safety profile, which avoids the immunosuppression risks of systemic corticosteroids and JAK inhibitors, distinguishes it from alternatives in ways that physicians reward with prescription volume. Sanofi S.A. Was formed in 2004 through the hostile takeover of Aventis, creating a French multinational biopharmaceutical company headquartered in Paris with 76,493 employees and a $107.8 billion market capitalization. FY2024 revenue of $44.6 billion made it one of the largest pharmaceutical companies in Europe. The company operates across immunology, rare diseases, oncology, vaccines, and general medicines — a portfolio breadth that reflects multiple decades of acquisition-driven diversification. The planned separation of the Opella consumer healthcare division in Q2 2025 is the most significant structural decision Sanofi has made in recent years. Removing $4.9 billion in consumer healthcare revenue transforms the company into a pure-play biopharma entity. The rationale is straightforward: consumer healthcare — over-the-counter products like Allegra and Doliprane — requires different manufacturing, distribution, marketing, and capital allocation than prescription biologics. The separation focuses capital and management attention on the high-margin biopharma business while potentially unlocking valuation for the consumer division separately. The $9.5 billion Blueprint Medicines acquisition in 2025, the largest transaction in the company's history in a single purchase, and more than $13 billion in total acquisitions in the first seven months of 2025 represent the most aggressive business development period Sanofi has executed, reflecting urgency to diversify the revenue base beyond the Dupixent dependency before that drug's competitive environment changes.

Eli Lilly and Company and Sanofi S.A. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Sanofi S.A..

Eli Lilly and Company business model: Lilly endured a lost decade marked by clinical failures in Alzheimer's disease research, insulin pricing controversies that drew congressional scrutiny, and generic competition that eroded blockbuster revenues. At its most fundamental level, Lilly's revenue model is straightforward: the company invests heavily in discovering and developing novel drugs, secures patent protection and regulatory approval for those drugs, manufactures them at scale, and sells them at premium prices to patients, healthcare systems, and payers. Insulin pricing has been a politically sensitive issue for Lilly, and in 2023 the company proactively announced it would cap monthly out-of-pocket costs for all insulin products at $35, a decision that absorbed short-term revenue impact but significantly reduced reputational and legislative risk. From a revenue geography perspective, the United States consistently represents the largest single market, accounting for approximately 65 percent of total revenues in 2024, reflecting both the premium pricing environment in American healthcare and the company's deep commercial infrastructure across hospitals, specialty pharmacies, and managed care organizations. The company's pricing and reimbursement strategy reflects the complex political economy of American pharmaceutical markets. Lilly's gross-to-net discount structure — the gap between list prices and the actual net prices after rebates, chargebacks, and discounts to payers and pharmacy benefit managers — has grown substantially as managed care organizations have exerted pricing pressure. Pricing and access policy represents a politically charged challenge with direct financial consequences. The Inflation Reduction Act of 2022 enable the Centers for Medicare and Medicaid Services to negotiate prices directly for high-expenditure drugs, and multiple Lilly products may become subject to negotiated pricing as the program expands in scope. The broader debate over pharmaceutical pricing, including congressional investigations and state-level legislative efforts, creates an ongoing environment of policy uncertainty that affects revenue planning and investor sentiment. Additionally, dozens of biotechnology companies and larger pharmaceutical corporations are developing oral GLP-1 agonists, next-generation dual and triple agonist molecules, and combination weight loss therapies that could fragment the market and compress Lilly's pricing power over the medium term.

Sanofi S.A. business model: The drug is co-developed and co-commercialized with Regeneron Pharmaceuticals under a 2007 collaboration agreement; Sanofi records global sales and shares profits with Regeneron, while paying royalties on net sales. This global footprint reduces dependence on any single market and provides access to high-growth emerging markets, though China faces pricing pressure from volume-based procurement. Third, Sanofi's vaccine division — while historically a strength and the world's largest dedicated vaccine business — faces pricing pressure and competitive threats. The pediatric vaccine market faces pricing pressure from government procurement. The Philippine FDA permanently revoked Dengvaxia's license in February 2019, and criminal investigations into Sanofi executives continue. Seventh, Sanofi faces regulatory and pricing pressure globally. In the US, the Inflation Reduction Act's Medicare drug price negotiation program could eventually affect Dupixent's pricing power. In China, volume-based procurement and national reimbursement drug list changes create pricing volatility, as evidenced by the 10.4% Q4 2024 sales decline attributed to inventory effects ahead of reimbursement changes. In Europe, reference pricing and health technology assessment requirements continue to constrain pricing flexibility. However, the 2030 peak sales target assumes continued pricing power and no significant biosimilar competition, both of which carry uncertainty.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Sanofi S.A..

Eli Lilly and Company competitive advantage: What makes Lilly's story particularly compelling is not just the scale of its recent success but the specific American geography it inhabits. The competitive landscape in which Eli Lilly operates has been radically reshaped over the past decade, both by the emergence of the GLP-1 drug class as a genuine blockbuster category and by the parallel evolution of oncology and immunology into scientifically sophisticated, targeted medicine domains where first-mover advantages and data depth matter enormously. Verzenio's revenue trajectory suggests it may eventually become the category leader despite entering the market after Ibrance, reflecting the value of superior clinical data over first-mover advantage in targeted oncology. The injectable nature of current tirzepatide formulations represents a patient acceptance barrier that, if removed through an effective oral alternative, would dramatically expand the addressable market. Eli Lilly's competitive advantages are rooted in four interconnected sources that, in combination, create a defensible position in the global pharmaceutical industry that goes beyond any single product success. This domain expertise is not merely historical; it manifests today in Lilly's pipeline of next-generation cardiometabolic molecules including orforglipron (an oral GLP-1 receptor agonist that could eliminate the injection barrier for millions of patients), retatrutide (a triple receptor agonist showing extraordinary weight loss results in Phase 2 trials — an average of 24.2 percent body weight reduction over 48 weeks), and other compounds targeting the intersection of metabolic disease, cardiovascular risk, and kidney function. Trust built through reliable insulin supply over a century translates into prescriber confidence in Lilly's newer products, creating a commercial starting advantage that newer entrants cannot replicate quickly. Fourth, Lilly's manufacturing infrastructure, while currently capacity-constrained, represents a long-term competitive moat. The technical complexity of sterile injectable biologics manufacturing creates meaningful barriers to generic and biosimilar entry, and the company's investments in dedicated tirzepatide manufacturing capacity will eventually provide scale advantages over potential competitors who face the same steep learning curves and capital requirements. By October 1923, Lilly was producing insulin on a commercial scale sufficient to supply diabetic patients across North America, and the company had developed an extract with substantially higher potency and reliability than earlier preparations.

Sanofi S.A. competitive advantage: In the COPD market, Dupixent faces competition from GSK's Trelegy Ellipta and AstraZeneca's Breztri Aerosphere, though Dupixent's position as the first biologic approved for COPD provides first-mover advantage. The second critical moat is the Dupixent-Regeneron collaboration, which dates to 2007 and represents one of the most successful pharma-biotech partnerships in history. Dupixent's first-mover advantage in IL-4/IL-13 inhibition, combined with its expanding indication portfolio across seven approved uses and multiple Phase 3 studies, creates a network effect where each new indication reinforces prescribing in existing ones. Sanofi's manufacturing scale represents a third competitive advantage. Sanofi's strategic pivot toward AI-driven drug discovery, through its plai platform and partnerships with entities including OpenAI, represents an emerging competitive advantage. Amitelimab, an anti-OX40L antibody for atopic dermatitis, demonstrated positive Phase 3 data in Q3 2025 with quarterly dosing — a significant convenience advantage over Dupixent's biweekly regimen.

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Sanofi S.A. each plan to expand from here.

Eli Lilly and Company growth strategy: That insulin partnership with the University of Toronto did not merely save lives; it established Lilly's identity as a science-first organization willing to pursue difficult biological problems across decades rather than quarters. Yet the company continued investing heavily in its research and development infrastructure, spending consistently between 20 and 25 percent of revenues on R&D even in lean years. Retevmo (selpercatinib), a RET kinase inhibitor for RET-altered cancers including certain lung and thyroid malignancies, and Jaypirca (pirtobrutinib), a BTK inhibitor for mantle cell lymphoma and chronic lymphocytic leukemia, represent Lilly's next-generation oncology assets with significant growth trajectories. Europe and Japan represent the next largest markets, with significant growth in emerging markets including China, where Lilly has maintained commercial operations for decades. This investment includes new sterile injectable fill-finish capacity and active pharmaceutical ingredient manufacturing to eliminate supply constraints that limited Zepbound and Mounjaro availability through much of 2023 and into 2024. The Indianapolis-based pharmaceutical company, which has survived Prohibition, the Great Depression, two World Wars, the AIDS crisis, multiple patent cliffs, and a decade of Alzheimer's drug failures, has in the early 2020s assembled what many analysts characterize as the most compelling pharmaceutical growth story of the current era. Ricks prioritized pipeline discipline over diversification, investing deeply in a small number of therapeutic areas where Lilly had genuine scientific depth rather than spreading resources thinly across many programs with mediocre differentiation. The company now invests more in R&D in absolute dollar terms than it generated in total revenues just fifteen years ago, illustrating both how dramatically the company has grown and how aggressively it is reinvesting to sustain that growth trajectory. For investors, healthcare professionals, policymakers, and patients, Lilly's evolution represents a case study in what pharmaceutical companies can achieve when long-term scientific commitment meets the right commercial moment. Lilly's competitive positioning in immunology is solid but not dominant, and the company's strategic priority is increasingly to defend existing Taltz revenues while investing in next-generation immunology candidates that could create new market leadership positions. This rate of growth is nearly unprecedented for a company of Lilly's scale in any industry, and it reflects almost entirely the commercial launch of tirzepatide across its Mounjaro and Zepbound indications. While Lilly's multi-billion-dollar manufacturing investment program is expected to alleviate these constraints by 2026 and 2027, the ramp-up period presents real financial and competitive risk, particularly as rival GLP-1 products from Novo Nordisk and potential new entrants compete for the same prescriber base and pharmacy shelf space. The irony is, Second, Lilly's brand equity among endocrinologists, cardiologists, and primary care physicians reflects decades of relationship-building through clinical education, medical affairs programs, and drug performance in real-world settings. Eli Lilly's growth strategy, as articulated through company investor presentations, earnings calls, and strategic communications under CEO David Ricks, rests on three interconnected pillars: maximizing the commercial potential of approved assets through indication expansion and market access improvement; sustaining pipeline productivity through disciplined internal R&D and targeted external business development; and building the manufacturing infrastructure necessary to support global demand at scale. The indication expansion strategy for tirzepatide is already well advanced. External business development has accelerated meaningfully under Ricks, reflecting a strategic recognition that internal R&D, while productive, cannot alone sustain the pipeline density required to replace revenue from products facing eventual patent expiry. Manufacturing investment represents the operational backbone of the growth strategy, with over $23 billion committed through 2027 to building capacity that will eliminate the supply constraints that have limited tirzepatide access and revenue since commercial launch. The trajectory of Eli Lilly over the next five to ten years is unusually legible by pharmaceutical industry standards, in large part because the company's near-term growth drivers are already approved and scaling and its longer-term pipeline candidates include multiple assets with multi-billion-dollar peak sales potential that have progressed to late-stage clinical development. Among the estimated 100 million Americans with obesity, fewer than 5 percent were receiving any pharmacological treatment as of 2024, suggesting an addressable population that could sustain revenue growth for many years even without new indications. New tirzepatide label expansions under investigation include heart failure with preserved ejection fraction (a trial already demonstrating positive results), sleep apnea, fatty liver disease (NASH/MASH), chronic kidney disease, and potentially cancer risk reduction. In Alzheimer's disease, donanemab (Kisunla) faces the challenge of building commercial infrastructure around a complex treatment model — patients require amyloid confirmation testing, infusion center visits, and MRI monitoring — but the underlying unmet medical need remains enormous, and Lilly is investing in diagnostic partnerships and infusion center networks to remove access barriers. The city was growing rapidly, positioned at the intersection of multiple rail lines that would increasingly define American commerce in the post-war era, and Lilly recognized both a business opportunity and a professional calling. He invested in analytical equipment to test raw materials before they entered production, a practice so unusual in the trade that it became a marketing point — Lilly medicines carried certificates of analysis years before regulatory bodies existed to require such documentation. This commitment to scientific integrity was not merely altruistic; it was a business strategy rooted in the belief that healthcare professionals, if given a choice, would prefer reliably effective medicines over cheaper alternatives that varied wildly in potency and purity. The company grew steadily through the late nineteenth century, expanding its product line from elixirs and tonics to a broader range of pharmaceuticals, moving into gelatin-coated capsules (a technology that significantly improved patient acceptance of medications) in the 1890s, and building a growing export business in Central and South America. The lesson of insulin — that patient, rigorous scientific investment in understanding complex biological mechanisms could produce far-reaching therapeutic outcomes — informed Lilly's research philosophy throughout the twentieth century and provides direct intellectual lineage to the GLP-1 and incretin research that would eventually produce tirzepatide seven decades later.

Sanofi S.A. growth strategy: That is Sanofi in 2024, a pharmaceutical giant whose fate has become inextricably linked to a monoclonal antibody born from a 2007 partnership with Regeneron Pharmaceuticals. This partnership structure means Sanofi retains approximately 55-60% of Dupixent's economics after Regeneron's share, though exact terms vary by territory. This segment faces structural decline as patents expire and biosimilars enter, with management actively streamlining the portfolio to focus on assets with remaining growth potential. The company's operating model emphasizes pipeline-driven growth, with management targeting high single-digit revenue growth in 2025 and low double-digit business EPS growth, supported by continued Dupixent expansion, new product launches, and operational efficiency initiatives expected to save $2.2 billion by end of 2025. Yet this same concentration creates vulnerability: if Dupixent's growth stalls or biosimilars arrive earlier than expected, Sanofi's revenue base would face a gap that the current pipeline cannot immediately fill. Management's guidance for high single-digit 2025 sales growth and low double-digit business EPS growth assumes successful execution of multiple parallel initiatives: COPD launch acceleration, tolebrutinib approval in MS, amitelimab Phase 3 success, and integration of acquired assets. Sanofi's AA credit rating and 30-year dividend growth streak provide financial stability, but the strategic challenge is unprecedented in the company's modern history. However, Sanofi's R&D productivity has historically lagged peers, with a lower rate of new molecular entity approvals per dollar invested compared to companies like Novartis and Roche. The 'Play to Win' strategy addresses this by prioritizing leading or first-in-class assets and reallocating resources from lower-priority areas like general oncology to immunology and rare diseases. Research and development expenses increased 14.6% to $8.1 billion ($8.0 billion), representing 18.0% of revenue, as Sanofi accelerated investment in pipeline assets including tolebrutinib, amitelimab, and the expanding Dupixent indication program. Full-year 2025 guidance anticipates high single-digit sales growth at CER and low double-digit business EPS growth before share buyback impact. In oncology, Sanofi is a relatively small player compared to Merck, Bristol Myers Squibb, and AstraZeneca, requiring significant investment to build competitive positioning. While the consumer healthcare unit is non-core to the biopharma strategy, the separation requires careful management of transition services, employee retention, and financial restructuring. Any delay or valuation disappointment would undermine investor confidence. This capability, if sustained, could accelerate pipeline development and reduce the time and cost required to replace Dupixent's eventual revenue contribution. Sanofi's growth strategy under CEO Paul Hudson's 'Play to Win' framework, first introduced in 2019 and updated in 2023, centers on four pillars: focus on key growth drivers, operational excellence, R&D prioritization, and strategic business development. The first pillar concentrates resources on Dupixent, rare diseases, vaccines, and new product launches while actively managing decline in General Medicines. In 2024, launches contributed 11% of total sales, up from 8% in 2023, with Beyfortus, ALTUVIIIO, and Nexviazyme as primary contributors. The 2025 guidance targets continued launch contribution growth as these products mature and new assets including tolebrutinib and amitelimab enter the market. These savings are being reinvested into R&D and commercial support for growth assets. In 2024, Sanofi reallocated resources from general oncology to immunology and rare diseases, reflecting a sharper strategic focus. The company is also investing in digital capabilities, including AI-driven drug discovery through the plai platform, digital twins for clinical development, and predictive analytics for supply chain optimization. Geographic expansion remains a priority, particularly in China where Sanofi faces near-term pricing pressure but maintains long-term growth potential, and in emerging markets where vaccine demand and access to specialty medicines continue to expand. Sanofi's strategic horizon is defined by three concurrent imperatives: maximizing Dupixent's remaining growth runway, building a pipeline capable of replacing its revenue contribution before patent expiration, and completing the transformation to a pure-play biopharmaceutical company. The pipeline replacement strategy centers on several high-potential assets. The vaccine pipeline includes next-generation influenza vaccines, mRNA platforms developed through the partnership with Translate Bio (acquired 2021), and combination vaccines. The strategic separation of Opella, expected to close in Q2 2025, will transform Sanofi's financial profile by removing a lower-margin, slower-growing business and enabling sharper focus on biopharma operations. The AI-driven drug discovery platform, plai, aims to reduce R&D costs and accelerate target identification, with reported success in identifying novel targets and optimizing clinical trial design. Jean-François Dehecq and René Sautier, two Elf executives, established Sanofi with a clear mandate: acquire fragmented pharmaceutical laboratories across France and build a consolidated European pharmaceutical group. The early business model was straightforward — a 'buy and build' investment vehicle financed entirely by Elf's capital reserves, without external seed funding. Within two years, Sanofi had integrated over ten small laboratories, overcoming skepticism from the medical establishment and establishing a culture of growth through acquisition. In 1980, Sanofi acquired the Clin-Midy group, significantly expanding its R&D capabilities and therapeutic breadth. The 1994 acquisition of Sterling Winthrop's prescription drug business provided critical US market access, establishing the transatlantic footprint that would prove essential for future growth. Elf Aquitaine and L'Oréal retained significant stakes, providing financial stability while the new entity focused on pharmaceutical R&D and marketing. Bioverativ added hemophilia therapies Eloctate and Alprolix, while Ablynx brought Nanobody technology and caplacizumab for acquired thrombotic thrombocytopenic purpura.

A closer look at the financial trajectory of Eli Lilly and Company and Sanofi S.A. rounds out the comparison.

Eli Lilly and Company: $9.3 billion spent on research and development in fiscal year 2024 — a number that exceeds Lilly's entire revenue base in 2009. That reinvestment rate, sustained over years, is the financial explanation for tirzepatide's commercial performance. Drugs of this clinical quality don't emerge from modest R&D budgets. Net income reached $10.59 billion in 2024 on $45 billion in revenue, a 23.5% net margin that reflects the pricing power of a drug that genuinely outperforms its competition. The revenue trajectory has been steep: $28.3 billion in 2021, $28.5 billion in 2022, $34.1 billion in 2023, $45 billion in 2024. Each year's jump is larger than the last, driven by tirzepatide's expansion across indications and geographies. The supply shortage controversy in 2023 had a real financial component. Manufacturing capacity for GLP-1 drugs requires specialized equipment and long lead times. Lilly has committed billions in capital expenditure to expand manufacturing — but the gap between demand and supply means some prescription revenue is being left on the table during a period when competitive dynamics are most favorable. The Loxo Oncology acquisition in 2019 cost approximately $8 billion. The oncology pipeline it delivered — including selpercatinib and other targeted therapies — now contributes revenue that diversifies Lilly's earnings away from the GLP-1 concentration risk. Market capitalization of $700 billion prices in continued GLP-1 dominance and successful Phase 3 outcomes for retatrutide. Either of those assumptions failing would reprice the stock significantly.

Sanofi S.A.: Dupixent's $14.3 billion in FY2024 sales exceeded the total annual revenue of most mid-cap pharmaceutical companies — generated by a single drug that Sanofi co-developed with Regeneron under a collaboration structure initiated in 2007. The Q3 2025 quarterly milestone of $4 billion in global Dupixent sales (and $3 billion in US quarterly sales) for the first time demonstrates the drug's continued growth trajectory even at significant scale. Total revenue grew from $40.8 billion in 2023 to $44.6 billion in 2024, with 2025 projected at $45.9 billion — growth driven primarily by Dupixent expansion as the drug adds patients across its seven approved indications. Net income of $6.2 billion on $44.6 billion in FY2024 revenue produces a 13.9 percent net margin, below the pharmaceutical industry's top-quartile margins because the heavy R&D investment and collaboration profit-sharing with Regeneron reduce the economic return that appears in Sanofi's own income statement. FY2024 R&D expenses reached $8.1 billion — a 14.6 percent increase from 2023 and the company's largest annual R&D investment in history. That urgency reflects the central financial vulnerability: $14.3 billion in Dupixent sales in a portfolio of $44.6 billion means the pipeline must produce significant revenue before Dupixent faces biosimilar competition, which becomes possible as patent protection periods expire in key markets. The Opella separation removes $4.9 billion in consumer healthcare revenue and is projected to drive operating margins toward 32 percent for the remaining pure-play biopharma entity. A 32 percent operating margin on the post-separation revenue base, combined with Dupixent's growth trajectory and the Blueprint Medicines pipeline, represents the financial argument for Sanofi's transformation from diversified pharmaceutical company to focused biopharma.